Analystreport

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $18.00 price target on the stock, d

Iovance Biotherapeutics, Inc.  (IOVA) 
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com